Table 2 Systemic therapies and oncological outcomes
Case | Systemic therapy | Best response (time to progression) | Oncological outcomes | Time from diagnosis of malignant TGCT |
|---|---|---|---|---|
1 | Doxorubicin + ifosfamide Gemcitabine + docetaxel Sirolimus (rapamycin) Sorafenib Sunitinib alone Sunitinib + sirolimus | SD (4 M) SD (3 M) N.A. (8 M) PD (mixed response) SD (15 M) PR (8 M) | DOD | 72 M |
2 | Sorafenib | PD | DOD | 20 M |
3 | Imatinib Doxorubicin + ifosfamide mTOR inhibitor PI3K/MTOR inhibitor Liposomal doxorubicin Ifosfamide Gemcitabine + docetaxel | PD PR (4 M) PD PD PD PD PR (5 M) | DOD | 23 M |
4 | Doxorubicin + ifosfamide Nilotinib Gemcitabine + docetaxel | SD (3 M) PD PD | DOD | 9 M |
5 | Doxorubicin (+/− an investigational drug) Paclitaxel Gemcitabine + vinorelbine | PR (6 M) PD PD | DOD | 17 M |
6 | Doxorubicin + ifosfamide Imatinib Pazopanib | N.A. PD (mixed response) Too short to evaluate(1 W) | DOD | 25 M |